万达生物制药 VNDA 深 沪
交易中 10-06 10:35:16 美东时间
4.445
-0.135
-2.95%
华盛通- 最 高5.64
- 今 开4.60
- 成交量 14.28万股
- 最 低 4.435
- 昨 收 4.58
- 总市值 25.11万
- 52周最高 9.94
- 市盈率 静 7.63
- 换手率 252.84%
- 52周最低 4.27
- 委 比 -5.66%
- 总股本 5.65万
- 历史最高 33.44
- 量 比 0.78
- 振 幅 26.31%
- 历史最低 1.10
- 每 手 1
- 风险率 1.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vanda Eyes First FDA-Approved Delayed Sleep-Wake Disorder Drug
Vanda's Phase 3 trial of HETLIOZ for DSWPD met its primary endpoint, advancing sleep onset by 42.5 minutes. sNDA submission planned.
09-30 21:10
Market-Moving News for February 23rd
VNDA: 54% | On Friday, The FDA Approved Vanda Pharmaceuticals' Bysanti (Milsaperidone) Tablets, A First Line Therapy For The Acute Treatment Of Manic Or Mixed Episodes Associated With Bipolar I Disorder And
02-23 20:20
Analyst Expectations For Vanda Pharmaceuticals's Future
In the last three months, 4 analysts have published ratings on Vanda Pharmaceut...
02-23 20:00
Earnings Outlook For Vanda Pharma
Vanda Pharma (NASDAQ:VNDA) is set to give its latest quarterly earnings report ...
02-11 04:01
FDA Approves Vanda Pharma Motion Sickness Drug, Fuels Upside
Analysts raise price targets for Vanda Pharmaceuticals after FDA approved a motion sickness drug, citing growth potential.
01-07 02:32
Nasdaq Moves Lower; US Crude Oil Inventories Decline Sharply
U.S. stocks traded lower midway through trading, with the Dow Jones index falli...
01-01 01:56
Why Is Vanda Pharmaceuticals' (VNDA) Stock Trending Overnight?
Vanda Pharmaceuticals' shares surged in after-hours trading following FDA approval of NEREUS for preventing motion-induced vomiting in adults.
2025-12-31 10:39
FDA Fast-Tracks Vanda's Motion Sickness Drug Review After Leadership Shake-Up
FDA accelerates re-review of Vanda's tradipitant and begins label talks, keeping its motion sickness drug on track for key 2025 decisions.
2025-11-29 00:10
Vanda Reports Big Win In Wegovy Support Study, Analysts Upbeat
Vanda's tradipitant cut Wegovy-related vomiting by 50% in a new trial, prompting bullish analyst views and price targets.
2025-11-21 02:59
中信证券：首予阜博集团(03738)“买入”评级 目标价8港元 看好全球维持版权保护长期需求
中信证券发布研报称，看好阜博集团(03738)投资价值公司，首次覆盖，给予“买入”评级。预计公司2025-2027年收入分别为29.79/37.38/47.1...
2025-08-14 11:49
